

Prevention - Recent Guidelines

- WHO – 2016
- ACS – 2016
- CDC – 2017
- ASHP – 2013*

*currently being revised



7

Published May 2023

SHEA Expert Guidance

Strategies to prevent surgical-site infections in acute-care hospitals: 2022 Update

Michael S. Calderwood MD, MPH^{1,3}, Deverick J. Anderson MD, MPH^{2,3}, Dale W. Bratzler DO, MPH³, E. Patchen Dellinger MD⁴, Sylvia Garcia-Houchins RN, MBA, CIC⁵, Lisa L. Maragakis MD, MPH⁶, Ann-Christine Nyquist MD, MSPH⁷, Kiran M. Perkins MD, MPH⁸, Michael Anne Preas RN, MS, CIC⁹, Lisa Saiman MD, MPH¹⁰, Marin Schweizer PhD¹¹, Joshua K. Schaffzin MD, PhD¹², Deborah S. Yokoe MD, MPH¹³ and Keith S. Kaye MD, MPH^{14,b}



8

Summary Table

Table 2. Summary of Recommendations to Prevent Surgical Site Infections (SSIs)

Recommendation	Quality of Evidence
1. Administer antimicrobial prophylaxis according to evidence-based standards and guidelines.	Quality of evidence: MOD
2. Use a combination of preoperative and intraoperative antimicrobial prophylaxis only in elective colorectal surgery to reduce the risk of SSI.	Quality of evidence: MOD
3. Administer topical antimicrobial prophylaxis in the preoperative setting for orthopedic and urologic procedures.	Quality of evidence: MOD
4. Administer topical antimicrobial prophylaxis in the preoperative setting for orthopedic and urologic procedures at high risk of multidrug-resistant SSI, such as those involving prosthetic material.	Quality of evidence: MOD
5. Use antibiotics containing antipseudomonal prophylaxis agents for patients undergoing creatine clearance or hemodialysis.	Quality of evidence: MOD
6. Do not administer oral antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
7. Do not administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
8. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
9. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
10. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
11. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
12. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
13. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
14. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
15. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
16. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
17. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
18. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
19. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
20. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
21. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
22. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
23. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
24. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
25. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
26. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
27. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
28. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
29. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
30. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
31. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
32. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
33. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
34. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
35. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
36. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
37. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
38. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
39. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
40. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
41. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
42. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
43. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
44. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
45. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
46. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
47. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
48. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
49. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
50. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
51. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
52. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
53. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
54. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
55. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
56. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
57. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
58. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
59. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
60. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
61. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
62. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
63. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
64. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
65. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
66. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
67. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
68. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
69. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
70. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
71. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
72. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
73. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
74. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
75. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
76. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
77. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
78. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
79. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
80. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
81. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
82. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
83. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
84. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
85. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
86. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
87. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
88. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
89. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
90. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
91. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
92. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
93. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
94. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
95. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
96. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
97. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
98. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
99. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD
100. Administer intravenous antibiotic prophylaxis to patients undergoing elective or emergency surgery.	Quality of evidence: MOD



9

Surveillance

- Direct vs. indirect methods
 - Indirect method reliable (sensitivity, 84%–89%) and specific (specificity, 99.8%) compared with direct surveillance
- Indirect combines
 - Review of microbiology reports and patient medical records
 - Screening for readmission and/or return to the operating room
 - Other information, such as coded diagnoses, coded procedures, operative reports, or antimicrobials ordered
 - Surgeon and/or patient surveys

Baker et al. AJIC 1995.
Cardo et al. ICHE 1993.



10

Surveillance – Electronic Data Helps

- Strategy 1 – antibiotics and readmissions
 - Improve the sensitivity and reduce effort
- Strategy 2 – diagnosis codes
 - Medicare claims data can be used to enhance traditional surveillance methods for SSI and to identify hospitals with unusually high or low rates of SSI

Chalfine et al. ICHE 2006.
Calderwood et al. ICHE 2013.
Huang et al. ICHE 2011.



11

Surveillance – Post-Discharge

- Important for internal review
- Not useful for hospital comparisons



12

Rates and Reporting

- Rate
 - Number of infections/100 procedures
- SIR – Standardized Infection Ratio
 - Number of observed infections/number of expected infections
 - >1 is bad
- Methods for risk adjustment exist, but are not very good



13

Example

- SSI following colon=10
 - Number of procedures=250
- NHSN says rate of colon SSI=2.0
 - So expected number of SSIs for 250 procedures would be 5 (5/250=2 SSI/100 procedures)
- $SIR = 10/5 = 2$



14

Basic Practices



15

15

Essential Practices

- Timing
- Dose
 - Re-dose?
- Duration
- Post-op glucose control
 - 110-150 mg/dL
 - Cardiac and non-cardiac
 - 24-48 hours after end of anesthesia (*uncertainty exists...*)



16

Timing and Dose - GOALS


1. Optimize serum and tissue concentration at the time of incision
2. Provide dose that ensure sufficient concentration during the procedure
3. Use agents that cover likely pathogens for the procedure



17

17

Prophylaxis: Ideal Scenario



18

Timing

- For most agents (e.g., beta lactams), administer within 60 minutes prior to incision
 - Mixed data on more specificity
 - Some data suggest improved outcomes if within 15-30 minutes
 - Allow for 2 hours for fluoroquinolones and vancomycin
- Unique scenarios
 - Administer prior to skin incision rather than after cord clamping for CSEC
 - Administer prior to inflating tourniquet

Duke Center for Antimicrobial Stewardship and Infection Prevention

19

Can Timing be Optimized?

- Cohort study
 - 158 Swiss hospitals
 - 538,967 patients (11 procedures)
- Timing of administration of cefuroxime and rate of SSI
- Mixed effects logistic regression
- Administration 10-25 minutes prior to incision was associated with decreased risk

Variable	OR (95% CI)	P-value
Timing of administration of antimicrobial prophylaxis (reference: prior to incision)		
0-30 min	0.85 (0.70-0.93)	<.001
31-60 min	0.91 (0.80-0.98)	.01
61-120 min	1.06 (0.95-1.18)	.38

Sommerstein et al. JAMA Netw Open 2023;6:e2317370

20

Weight-based Dosing

- Cefazolin
 - 2g if <120 kg
 - 3g if ≥120 kg
 - 30 mg/kg for pediatric patients
- Vancomycin 15 mg/kg
- Gentamicin 5 mg/kg
 - For morbidly obese patients, use the ideal weight plus 40% of the excess weight for dose calculation
 - NOTE: Use of single dose for prophylaxis **not** associated with renal injury

Duke Center for Antimicrobial Stewardship and Infection Prevention

21

Obesity is a Risk Factor for SSI

- Numerous studies have shown that obesity is an independent risk factor for SSI
 - Increased rates of SSI of 2 to 6 times higher than non-obese patients
- Why? Likely combination of technical and pharmacologic factors
 - Poorly vascularized tissue
 - Strong correlation between amount of SQ/intra-abdominal fat and risk of SSI
 - Decreased tissue oxygenation among obese patients
 - Creation of dead space
 - Fat > 3.4 cm
 - Patients often have other co-morbid illnesses such as diabetes mellitus and CV disease

Choban et al. Am Surg. 1995;61(11):1001-5.
Nagachima et al. J Infect Dis. 1987;156(6):967-73.

22

Tissue Concentration

- Adipose tissue has far smaller concentration of antibiotic than blood
 - 10% of blood concentration
 - The more adipose tissue, the smaller the concentration
- Administered 2g of cefotetan prior to colorectal surgery (n=16)
 - Measured antibiotic concentration in serum, skin fat and gut fat

Martin et al. Antimicrob Agent Chemother 1992;36:1115-8.

23

Prophylaxis: Obesity

Duke Center for Antimicrobial Stewardship and Infection Prevention

24

3g v. 2g Cefazolin: Outcomes

- Review of >38,000 hip procedures
 - >2000 patients >120 kg
 - 75% were underdosed (received 2g)
- Patients underdosed were >2-fold higher risk of SSI compared to appropriate dosing
- Excellent safety profile, even with higher dosing

Morris et al. AJHP 2020;77:434.

25

Duration

- OLD: stop within 24 hours of surgery
- Numerous meta-analyses fail to demonstrate any benefit of prolonged prophylaxis
 - Even if drain left in place
 - Systematic review: single dose vs. multiple dose (24 hour)
 - SSI OR 1.04 [0.86-1.25]
- No benefit, but increased risk of harm
 - C. difficile*
 - Antibiotic resistance
 - AKI
- NEW: stop at surgical closure**

McDonald et al. Aust NZ J Surg 1998. Miranda et al. JACS 2020;231:766. Takemoto et al. JBJS Am 2015

26

Increased Duration and Adverse Events

79,058 surgical patients in VA system

Branch-Elliman et al. JAMA Surgery 2019;154:590

27

Expand the Details – More Essential Practices (Part 2)

- Re-dosing for prolonged procedures
 - Prolonged surgical duration is risk factor for SSI
- Bowel prep
 - NEW: give a combination of parenteral and oral antimicrobial prophylaxis prior to elective colorectal surgery (HIGH)**

28

Prophylaxis: Long Procedure

Optimal Drug Concentration To Kill Bacteria

29

Re-Dosing: Outcomes

- Analysis of 801 patients undergoing clean-contaminated operations:
 - If procedure > 3 hours, then rate of SSI reduced from 6.1 to 1.3 with additional dosing

Antimicrobial	Adults*	Half-life in Adults With Normal Renal Function, hr†	Recommended Redosing Interval From Initiation of Preoperative Dose, hr
Ampicillin	2 g	1.3-1.8	2
Amoxicillin	3 g	1.5-2.0	4
Cefazolin	2 g, 3 g for patients weighing >120 kg	1.2-2.2	4
Cefuroxime	1.5 g	1.2-1.1	4
Cefepime	2 g	2.0-3.7	2
Ceftazidime	2 g	2.0-1.1	2
Ceftriaxone	2 g	2.0-4.0	2
Cloxacillin	2 g	1.4-3.0	NA
Clotrimazole	500 mg	3-7	NA
Clindamycin	900 mg	2-4	NA

Scher KS. Am Surg 1997;63:59-62. ASHP Guidelines 2013.

30

Mechanical Bowel Prep + PO Abx

- Frequently overlooked
- Evidence based
 - Combine MBP + PO Abx + parenteral Abx
 - MBP alone does not reduce risk of SSI

Best Practice for SSI Prevention	Compliance with Best Practice, n/N (%)
Choice of prophylactic antibiotic(s)	578/643 (90%)
Timing of prophylactic antibiotic(s)	534/643 (83%)
Weight-based dose of prophylactic antibiotic(s)	557/643 (87%)
Re-dosing of prophylactic antibiotic(s)*	44/77 (57%)
Skin antiseptic with appropriate agent	528/643 (82%)
Maintenance of perioperative normothermia	467/643 (73%)
Operative and postoperative supplemental oxygen ^b	89/503 (18%)
Postoperative glucose monitoring and control	264/643 (41%)
Use of SSI prevention checklist	195/643 (30%)
Prophylactic oral antibiotics and mechanical bowel preparation^c	28/217 (13%)

Baker et al. eClinicalMed 2022;54:101698

31

MBP + PO Abx vs. MBP alone

Systematic Review of 40 studies

Rollins et al. Ann Surg 2019; 270:43-58.

32

Harm?

Decreased risk of anastomotic leak with MBP + PO Abx

Rollins et al. Ann Surg 2019; 270:43-58.

33

In fact, Consensus Recommendation!

- Three major guidelines recommend the use of MBP + PO antibiotics + Parenteral Abx for colorectal procedures
 - SHEA/IDSA
 - WHO
 - ACS/SSI

(not discussed in CDC/HICPAC)

34

Post-op Glycemic Control

- New recommendations:
 - Emphasize REGARDLESS of diabetes diagnosis
 - Lower target to 110-150 mg/dL


35

Post-op Glycemic Control

- Surgical Care and Outcomes Assessment Program in Washington State
 - 11,633 patients (57% colorectal)
- Notes
 - 25% had glucose >180
 - Hyperglycemia = 2-fold increase in SSI risk
 - Adjusted

Kwon et al. Ann Surg 2013;257:8-14.

36



37

- ### How?
- RCT of basal-bolus insulin vs. SS insulin
 - 211 general surgery patients with diabetes
 - Results
 - 3.4-fold decrease in composite outcome
 - SSI, pneumonia, BSI, resp/renal failure
 - Average post-op glucose 145 v. 172 (p<0.01)
 - No statistically significant difference in patients with BG<40, but close (4 v. 0, p=0.06)
- Source: Umpierez et al. Diabetes Care 2011;34:256-61.

38

- ### Essential Practices – Part 3
- Antiseptic prep
 - Wound lavage
 - WHO checklist
 - Bundles
 - Screening and decolonization for *S. aureus*
- Source: Duke Center for Antimicrobial Stewardship and Infection Prevention

39

- ### Antiseptic Prep
- Use alcohol-containing skin prep (when possible)
 - Add a disinfectant
 - CHG likely superior to PI
 - 4 RCTs
 - **NEW: use antiseptic-containing preoperative vaginal preparation agents for patients undergoing CSEC or HYST**
 - PI or CHG
 - No alcohol
- Source: Duke Center for Antimicrobial Stewardship and Infection Prevention

40

CHG Uses in Infection Control


Application	Evidence
Skin antiseptics	
CVC site preparation	50% better than povidone-iodine (catheter colonization)
Surgical hand scrub	86-92% reduction in flora
Source control in ICUs	Reduction in skin flora; reduce risk of CLABSI 6-fold
Preoperative scrub	Superior to other antiseptics in reducing skin flora at surgical site
Impregnated devices	
Vascular catheter dressings	Reduction in catheter colonization (40-50%); decrease rate of CLABSI
Vascular catheters	Reduction in catheter colonization (55%); in BSI (40%) in high-risk groups

Source: Misono et al. Clin Infect Dis 2008; 46:274-81; Bleasdale et al. Arch Intern Med 2007; 167:2073-9; Timat et al. JAMA 2009; 301:1231-41.

41

- ### CHG v. PI?
- RCT comparing CHG-ETOH vs. PI-ETOH
 - 1,147 women undergoing CSEC
 - Rate of SSI lower with CHG/ETOH (p=0.02)
 - CHG/ETOH – SSI rate=3.0
 - PI/ETOH – SSI rate=4.9
- Source: Tuuli et al. NEJM 2016;374:647.

42




43

Wound Lavage

- Commonly performed, little standardization
 - Lots of papers, but most reviews still consider evidence to be "low quality"
- What to use?
 - Saline - **NO**
 - Antiseptic - **YES**
 - Antibiotic - **MAYBE (but not preferred)**
- Bacitracin contraindicated
 - FDA requested withdrawal from market

44



45

Antiseptic vs. Antibiotic Lavage

- Systematic review and meta-analysis of 21 RCTs
 - Dilute povidone-iodine decreased risk of SSI
 - OR=0.31, 95% CI 0.13-0.73
 - No benefit from antibiotic lavage
- More recent, larger review (n=42 RCTs)
 - Dilute PI decreased risk (OR 0.57 [95% CI 0.32-0.95])
 - Abx lavage decreased risk (OR 0.44 [95% CI 0.28-0.67])
- Benefit of antibiotic irrigation may be limited to clean-contaminated or contaminated procedures
- Take Away: prefer use of PI
 - Weight of data supports its use
 - Avoid further antibiotic exposure
- POINT of EMPHASIS: How to obtain "STERILE" PI?**

De Jonge et al. Surg Infect 2017;18:508. Thom H et al. Surg Infect 2021;22:1144.

46

Checklists and Bundles

- Should we use them? **YES**
- What are the best components to include?
 - Not well known

47

Surgical Safety Checklist

- Checklists
 - Proven method for prevention of complications
 - Change system AND individual behavior
 - CLASI
- New checklist for surgical care
 - 19 item surgical safety checklist
 - Sign in, Time out, Sign out
 - 8 institutions throughout world
 - Prospective, quasi-experimental study of patients before (n=3733) and after (n=3955) implementation
 - Non-cardiac surgery
 - During "Time-Out," OR team had to confirm that prophylactic antibiotics have been administered ≤60 min before incision is made or that antibiotics are not indicated

Pronevost et al. N Engl J Med 2006;355:2725-32. Haynes et al. N Engl J Med 2009;360:491-9.

48

Surgical Safety Checklist

Table 2. Characteristics of Participating Hospitals.

Site	Location	No. of Beds	No. of Operating Rooms	Type
Prince Hamzah Hospital	Amman, Jordan	500	13	Public, urban
St. Stephen's Hospital	New Delhi, India	733	15	Charity, urban
University of Washington Medical Center	Seattle, Washington	410	24	Public, urban
St. Francis Designated District Hospital	Ifakara, Tanzania	371	3	District, rural
Philippine General Hospital	Manila, Philippines	1800	39	Public, urban
Toronto General Hospital	Toronto, Canada	744	19	Public, urban
St. Mary's Hospital ^a	London, England	541	16	Public, urban
Auckland City Hospital	Auckland, New Zealand	710	31	Public, urban

Haynes et al. N Engl J Med 2009;360:491-9.

49

Surgical Safety Checklist

Site No.	No. of Patients Enrolled		Surgical-Site Infection		Prophylactic Antibiotics Given Appropriately (N=6802)		Death		Any Complication	
	Before	After	Before	After	Before	After	Before	After	Before	After
1	524	508	4.0	2.0	98.1	96.9	1.0	0.0	11.6	7.0
2	357	351	2.0	1.7	96.9	76.9	1.1	0.3	7.8	6.3
3	497	486	5.8	4.3	83.8	87.7	0.8	1.4	13.5	9.7
4	520	545	3.1	2.6	80.0	81.8	1.0	0.6	7.5	5.5
5	370	330	20.5	3.6	29.8	96.2	1.4	0.0	21.4	5.5
6	496	476	4.0	4.0	25.4	50.6	3.6	1.7	10.1	9.7
7	525	585	9.5	5.8	42.5	91.7	2.1	1.7	12.4	8.0
8	444	584	4.1	2.4	18.2	77.6	1.4	0.3	6.1	3.6
Total	3733	3955	6.2	3.4	56.1	82.6	1.5	0.8	11.0	7.0
P value			<0.001		<0.001		0.003		<0.001	

Haynes et al. N Engl J Med 2009;360:491-9.

50

Colorectal Bundle

- High adverse outcomes following colorectal procedures (>20%)
 - ACS-NSQIP data
- Created and implemented a "bundle" of evidence-based and "common sense" interventions
 - Multidisciplinary
 - Monthly review meetings
 - Items included on a "checklist"

Keenan et al. JAMA Surg 2014;149:1045.

51

Bundle Components

Preoperative	Operative	Postoperative
Chlorhexidine shower	Facial wound protector	Removal of staple/dressing within 48 h
Mechanical bowel preparation with oral antibiotics	Gown and glove change before facial closure	Daily washings of incisions with chlorhexidine
Wound preparation within 1 h of incision	Dedicated wound closure tray	
Maintenance of preparation of surgical field with chlorhexidine alcohol	Limited OR traffic	
	Maintenance of normothermia	
	Maintenance of normothermia during surgery and in the early postoperative period	
Patient education and reinforcement of SSI prevention measures and objectives		

Keenan et al. JAMA Surg 2014;149:1045.

52

Results

- Retrospective analysis of 559 randomly selected patients from 2008 through 2012
 - Propensity matched on multiple potential confounders (age, sex, BMI, DM, chemo, XRT, total op time, lap approach, rectal)
 - 212 patients in each group
 - No major differences in patient characteristics

Keenan et al. JAMA Surg 2014;149:1045.

53

Results

	Prebundle (n=212)	Postbundle (n=212)	p-value
Superficial-incisional SSI	41 (19.3)	12 (5.7)	<0.001
Deep-incisional SSI	3 (1.4)	0	0.25
Organ-Space SSI	11 (5.2)	6 (2.8)	0.32
Wound disruption	5 (2.4)	3 (1.4)	0.72
Postop sepsis	18 (8.5)	5 (2.4)	0.009
LOS - med (IQR)	5.5 (4-8)	5.0 (3-7)	0.05
30-d readmit	32 (15.1)	19 (9.0)	0.14

Keenan et al. JAMA Surg 2014;149:1045.

54


Glove/Instrument Change

- ACS/SIS recommended changing gloves and instruments for closure in colorectal surgery
- Based on expert consensus
- Frankly, not a bad idea

55

S. aureus Screening/Decolonization

- MRSA gets the attention, but emphasis should be on both MSSA and MRSA
- If known to be colonized, should decolonize
 - ASHP, WHO, ACS, SHEA
- BUT - Should you screen??
 - Controversial!



56

S. aureus Decolonization


- Standard decolonization: intranasal mupirocin + CHG bathing
 - Alternatives exist
- Most support from orthopedic and cardiothoracic literature
 - Clean procedures
 - Meta-analysis of 17 studies concluded that decolonization strategies prevent *S. aureus* SSI
 - At least two RCTs
- Not as much support when other procedures studied
- New recommendation:**
 - Decolonize ortho and CT procedures
 - Decolonize other procedures at high risk of staph SSI (i.e., prosthetic material)

57

S. aureus Decolonization

20 hospital study, using a bundle to reduce risk of *S. aureus* SSI

Included screening and decolonization



Schweizer et al. JAMA 2015;313:2162.

58

Screening/Decolonization Considerations

- Many factors to consider
 - Baseline rate of *S. aureus* SSI
 - Ability to follow up culture results
 - Resources to implement protocol
 - How to screen? How to decolonize?
 - Create mupirocin resistance? Availability?
- Some modeling data suggest universal decolonization may be more cost effective than screening and treating

59

Intranasal Povidone Iodine

- Alternative approach with antiseptic agent instead of antibiotic
 - Won't drive antibiotic (mupirocin) resistance
 - Still couple of skin antiseptics (chlorhexidine)
- Easier approach – can be given pre-operative setting instead of requiring 5 days prior to the procedure
 - Effect likely not as long lasting
- One single center RCT of 855 patients with spine or joint procedure
 - No difference in overall SSI rate or *S. aureus* SSI rate between mupirocin and intranasal PI

60

Essential Practices – Part 4

- Don't shave skin
- Maintain normothermia
 - Devices make easier
 - Only in procedures with general anesthesia



61

Supplementary Strategies – To Do or Not?

- Negative pressure wound therapy
- Supplemental oxygen
- Use of vancomycin
 - Vancomycin powder
- Antimicrobial sutures



62

Negative Pressure Wound Therapy

- Routine use of prophylactic negative pressure wound therapy has not been shown to decrease SSIs
- Prophylactic negative pressure wound therapy on primarily-closed, high-risk surgical wounds may decrease SSI risk vs. standard wound dressings
 - Low quality evidence cited in ACS and WHO guidelines
 - High-risk wounds: surrounding soft tissue damage, poor blood flow, hematoma, or intraoperative contamination
- The pressure level or duration of negative pressure therapy needed to maximize SSI risk reduction is not known



63

Negative Pressure Wound Tx

- Large, randomized clinical trial of SSI after CSEC
- Enrolled 1624, stopped due to futility

Table 3. Primary and Secondary Outcomes by Randomization Group

Outcome	No. (%)	Relative risk (95% CI)*	Standard deviation (95% CI)*	Relative risk difference (95% CI)*	Relative risk (95% CI)*	P value†
Primary outcomes						
Superficial or deep surgical site infection	29 (1.6)	27 (1.6)	0.06 (-0.06 to 0.18)	1.05 (0.82 to 1.34)	70	
Predefined secondary outcomes						
Subcategories						
Superficial surgical site	18 (1.0)	18 (1.0)	0.04 (-0.06 to 0.13)	1.12 (0.97 to 1.28)	38	
Deep surgical site†	11 (0.6)	11 (0.6)	-0.04 (-0.20 to 0.14)	0.96 (0.62 to 1.40)	25	
Organ-space surgical site†	1 (0.05)	1 (0.05)	0.00 (-0.04 to 0.04)	0.97 (0.24 to 4.00)	1	
Other wound complications	23 (1.3)	23 (1.3)	-0.13 (-0.33 to 0.08)	0.83 (0.47 to 1.47)	46	
Site reoperation	11 (0.6)	11 (0.6)				
Revisits	1 (0.05)	1 (0.05)				
Hospital stay	4 (0.2)	4 (0.2)				
Fatality	1 (0.05)	1 (0.05)				

Tuuli et al. JAMA 2020;1180-1189.



64

Oxygen and SSI: Basic Science

- O₂ is important for wound healing
- O₂ correlated with collagen deposition
- Tissue hypoxia is a risk factor for wound infection and dehiscence
- Superoxide production by leukocytes proportional to P_{O2}
- Many antibiotics require oxygen to exert lethal effects on bacteria

Hurt and Pals. Surg Oxygens. 1972;135:561-7
 Hartmann et al. Eur J Surg. 1992;158:52-5.
 Hall et al. Arch Surg. 1997;132:997-1004.
 Allen et al. Arch Surg. 1997;132:997-1005. Kohanski et al. Cell. 2007;150:797-810.



65

High Inspired O₂ Fraction

- Meta-analysis reviewed 5 RCTs
 - Variation in methods noted
 - 3 included nitrous oxide mixture
 - 1 provided O₂ for 6 hours
 - 3 colorectal
 - Antibiotic prophylaxis not controlled for in all
- By fixed-effects method, data supports use of 80% FIO₂ for prevention of SSI
- Previous guidelines – Essential Practice



Qadan et al. Arch Surg. 2008;144:339-68.
 Nagibano L. Arch Surg. 2009;144:366-67.

66

Supplemental Oxygen: What Happened After 2014?

- 2022 Compendium: **Unresolved**
 - Optimize tissue oxygenation at the incision site
- Meta-analyses performed including additional studies
 - No significant impact of supplemental oxygen
 - Although "trend" towards SSI prevention still there

Shaffer et al, AANA Journal, 2021, Vol. 89, No. 3

67

What about IV Vancomycin?

- Discouraged
 - Indication for need significantly reduced
 - May have value during proven outbreak of MRSA SSI
 - No head-to-head comparison with decolonization strategy previously described
- Previously, "high rate" of MRSA SSI was potential indication
 - Retrospective cohort of 79,092 surgical patients
 - Perceived high rate of MRSA SSI was primary reason for use of vancomycin
 - Rate of colonization no higher
 - Rate of SSI no different
 - AKI higher
- Other studies also point to increased adverse events

68

What about IV Vancomycin?

- Even though "covers" MRSA, vancomycin has decreased coverage compared to beta-lactams
 - No Gram negative activity
 - Reduced MSSA activity
- Some experts argue that should **add** vancomycin to standard agents when needed
 - Cohort study of 70,101 VA surgical patients receiving beta lactam, vanco, or both for prophylaxis
 - Combination led to higher rates of AKI than either alone
 - Combination led to lower SSI rate for cardiac procedures but not for ortho, vascular, GYN, or colorectal procedures

Branch-Elliman et al. PLOS Med 2017;14:e1002340

69

Vancomycin Powder?

- "Unresolved" issue
 - Several single center quasi-experimental studies found a lower rate of SSI in spinal surgery with the use of vancomycin powder
 - Others noted significant increase in the proportion of SSI with polymicrobial and Gram-negative pathogens
- RCT of 907 spinal procedures
 - Prophylactic abx vs. prophylactic abx + vancomycin powder
 - No difference in SSI outcomes
 - Small numbers
- Overall, no high quality data to support

Tubaki et al. Spine 2013;38:2149.

70

Antiseptic-Impregnated Sutures

- Presence of sutures decreases bacterial inoculum needed to cause SSI
 - 1,000,000 -> 100
- But data not convincing

Chang et al. Ann Surg 2012;255:854

71

Supplementary Strategies – To Do or Not?

- Negative pressure dressings
 - Can be used as an **Additional Practice**
- Supplemental oxygen
 - Don't know ("unresolved")*
 - Now demoted*
- Use of vancomycin – **expanded discussion**
 - Not routine**; try to avoid
 - May have special indications
 - Powder? **Unresolved**
- Antimicrobial sutures
 - Can be used as an **Additional Practice**

72

Take Home Points

- SSI is the most costly HAI
- Many different strategies are required to reduce SSI risk to lowest extent possible
- IPs play a critical role
- Not every hospital needs to approach SSI prevention the same way
 - But all hospitals need to review and use the essential strategies



73

Questions?

dcasip.medicine.duke.edu

74